LY96 and Sepsis: Therefore, new therapeutic molecules have been developed to prevent uncontrolled bacterial endotoxin-mediated sepsis by targeting the LPS-stimulated TLR4 signaling pathway to develop new antagonists by targeting TLR4 and MD-2 [47,48].